<DOC>
	<DOCNO>NCT00021112</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy radiation therapy surgery treat patient stage IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Followed Surgery Treating Patients With Stage IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine incidence radically resect disease patient stage IIIB non-small cell lung cancer treat induction cisplatin , etoposide , radiotherapy follow surgical resection . - Determine toxicity ( morbidity mortality ) regimen patient . - Determine clinical response rate pathological response rate patient treat regimen . OUTLINE : This multicenter study . Patients receive induction chemotherapy comprise cisplatin IV day 1 etoposide IV day 1-3 . Chemotherapy repeat every 3 week 3 course . Beginning day 2 second course chemotherapy , patient undergo induction radiotherapy daily 5 day week 5-7 week . Chemoradiotherapy continue absence disease progression unacceptable toxicity . At 3-6 week completion last dose induction radiotherapy , patient undergo lobectomy pneumonectomy . Patients follow 30 day 4 month , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 27-62 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary stage IIIB nonsmall cell lung cancer ( NSCLC ) T4 , N , M0 T , N3 , M0 No N3 disease due scalene supraclavicular lymph node involvement No primary tumor locate low lobe combine contralateral upper high mediastinal lymph node involvement No mixed tumor type small cell lung cancer At least 1 unidimensionally measurable target lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan No preexist pleural pericardial effusion No CNS involvement CT scan MRI PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm ^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.25 time ULN Creatinine clearance least 60 mL/min Cardiovascular : No clinical evidence superior vena cava syndrome Pulmonary : Postoperative FEV1 KCO great 40 % predict VO2 max great 15 mL/min/kg ( postoperative KCO great 40 % predict ) Other : No primary malignancy except carcinoma situ cervix , adequately treat basal cell skin cancer , malignancy treat 5 year ago without recurrence ( exclude melanoma , breast cancer , hypernephroma ) No active uncontrolled infection require IV antibiotic No preexist sensory neurotoxicity grade 2 great No psychological , familial , sociological , geographical condition would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy NSCLC No concurrent immunotherapy induction chemoradiotherapy Concurrent colony stimulate factor allow Chemotherapy : No prior chemotherapy NSCLC Endocrine therapy : No concurrent anticancer hormonal agent ( except corticosteroid antiemetic prophylaxis ) induction chemoradiotherapy Radiotherapy : No prior radiotherapy NSCLC Surgery : No prior surgery NSCLC Other : No concurrent anticancer drug induction chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>